SGLT2 Inhibitor (Type 2 Diabetes)Conditionally Approved

Canagliflozin

Brand names: Invokana|Last verified: 2026-03-01

FAA Pathway: Special Issuance (Diabetes Protocol)

Canagliflozin is an SGLT2 inhibitor available through the FAA diabetes Special Issuance pathway. Like empagliflozin, documentation must confirm no DKA risk and stable glucose control.

Check your medications

Look up any medication in our FAA compatibility database.

Medication Checker

Related Resources

Pilot Tip

Always report all medications on your FAA medical application (Form 8500-8, Item 17a), even OTC medications. Failure to disclose is a far bigger issue than the medication itself.

Certification Details

Key Requirements

A1C monitoring, no DKA, stable renal function

Certificate Classes

1st, 2nd, and 3rd class eligible

Monitoring

Quarterly A1C, renal function

Notes

Higher amputation risk noted — discuss with AME if applicable

Sources

FAA AME Guide — Pharmaceuticals: Diabetes Type II (faa.gov/ame_guide/pharm/oral_diabetes)

Last verified: 2026-03-01

Frequently Asked Questions

Is Canagliflozin allowed for pilots?

The FAA considers Canagliflozin (Invokana) to be "Conditionally Approved" for medical certification purposes. Canagliflozin is an SGLT2 inhibitor available through the FAA diabetes Special Issuance pathway. Like empagliflozin, documentation must confirm no DKA risk and stable glucose control.

What is the FAA status of Canagliflozin?

Canagliflozin has a status of "Conditionally Approved" under FAA medical certification policy. The certification pathway is: Special Issuance (Diabetes Protocol).

Can I fly while taking Canagliflozin?

Flying while taking Canagliflozin may be possible through the FAA's Special Issuance process. You will need to meet specific requirements and obtain approval before exercising pilot privileges. Consult an experienced AME for guidance.

Important Notice

The FAA does not publish a comprehensive list of “approved” medications. The information on this page represents our interpretation of publicly available FAA guidance and is provided for informational and educational purposes only. It does not constitute medical advice, legal advice, or a guarantee of certification outcome.

The primary issue with the FAA is always whether the underlying medical condition — not just the medication — is compatible with safe flight. You should only start, stop, or change medications after consulting your treating physician. Always consult with a qualified Aviation Medical Examiner (AME) for guidance specific to your situation. FAA policies are subject to change. ClearedMed is not affiliated with or endorsed by the FAA.